ArticleJournal of translational medicine2026
Lineage-specific immune checkpoint dynamics define a context-dependent regulatory framework with translational relevance in human γδ T cells.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune checkpoint receptors (ICRs) are widely used as markers of T-cell exhaustion, yet their interpretation remains context-dependent and is poorly described in γδ T cells. Here, we investigated the dynamics, functional impact, and differentiation-associated distribution of ICRs across human γδ and αβ T-cell subsets.
methodsPeripheral blood mononuclear cells from healthy donors were stimulated in vitro to assess ICR dynamics in γδ and αβ T-cell subsets by flow cytometry. Functional effects of PD-1 and TIM-3 blockade were evaluated through proliferation, cytokine production, and degranulation assays. In parallel, previously published single-cell RNA-sequencing datasets of tumor-infiltrating γδ and CD8 T cells were subjected to secondary bioinformatic analysis to characterize differentiation-associated ICR expression patterns and their modulation following immune checkpoint blockade (ICB) therapy.
resultsICR expression was regulated in a receptor-, lineage- and context-dependent manner. Polyclonal stimulation induced broad ICR upregulation, whereas phosphoantigen-driven Vδ2 T cell expansion resulted in a selective profile with sustained TIM-3 expression and transient modulation of PD-1 and TIGIT. Checkpoint distribution was structured across differentiation states, with TIGIT enriched in antigen-experienced subsets, LAG-3 and TIM-3 in naive compartments, and PD-1 broadly expressed. PD-1 blockade was associated with donor-dependent trends toward increased proliferation and cytokine production, particularly under IL-15 stimulation, whereas TIM-3 inhibition showed variable effects and combined blockade did not produce a consistent additive response. Single-cell transcriptomic analyses revealed that tumor-infiltrating γδ T cells displayed heterogeneous ICR expression across differentiation states, whereas CD8 T cells showed a more progressive pattern of checkpoint expression. Because classical exhaustion-associated transcriptional and epigenetic programs were not evaluated, these patterns neither establish nor exclude the presence of exhausted γδ T-cell subsets. ICB therapy was associated with persistence or upregulation of alternative checkpoints.
conclusionsThese findings indicate that ICR expression in γδ T cells is dynamically shaped by activation, differentiation, and environmental context. However, ICR expression alone is insufficient to define or exclude a state of T-cell exhaustion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.